Moderna Inc MRNA

$190.01 +1.07 (0.57%)

Valuation

Market cap
75,431,648,000
Revenue TTM
$1,944,000,000
Net income TTM
$-2,822,000,000
PE ratio
0.00
Forward PE
—
Profit margin
-145.16%
Debt to equity
0.09

Trading

Volume
10,289,400
Avg volume
20,080,861
Day's range
$183.28 – $193.72
Shares out
399,236,000
Stochastic %K
53%
Beta
1.09
Analysts
Sell
Price target
$123.00

Price

Company profile

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public...

Show more

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 714 6500
Website
https://www.modernatx.com
Address
325 Binney Street, Cambridge, United States

Latest news

Stocktwits

PaidGuruWorstNightmare Oct 3, 8:47 PM
$SPY $BTC.X $GLD.X $MRNA @theoptionsplug @OMillionaires @TheProphetOfProfit @KXTrading Stay quiet & keep getting exposed for the grifters you are. https://www.youtube.com/watch?v=4fWyzwo1xg0
0 replies
PaidGuruWorstNightmare Oct 3, 8:41 PM
$SPY $BTC.X $GLD.X $MRNA @theoptionsplug @OMillionaires @TheProphetOfProfit @KXTrading Everyone with eyes & a brain sees you've been obsolete for years. https://x.com/MomoEdgeAI/status/2106481692756095275
0 replies
55X_ROI_Q1_2026 Oct 3, 6:36 PM
$SLS Gps Phase 3 MOS for CR2/3 Second and Third Remission Patients will come in > 34 Months, LONGER than BAT for CR1 First Remission Patients 24.7 months. Gps Phase 3 MOS > 34 Months in Second Remission (CR2) Patients is LONGER than BAT for First Remission (CR1) 24.7 months. • SLS Value will absolutely include the CR1 Market: 50,000 AML Patients get into a First Remission CR1 Each Year. 5+ Year Dosing • $740K Rev Per Patient ​ • $37B Total Addressable Global Market for First Remission AML Maintenance. This Short Rigged $2.3B BABY BIO will be Growing up fast, and will add Tens of Billions in Market value - the instant the Imminently Due P3 Results are Announced. Will Make make the $MRNA +$50B Run based on its P3 cancer Vaccine Results look Anemic.
0 replies
lrn_2_invest Oct 3, 4:48 PM
$MRNA 210 call 11/06.
0 replies
Kingjake26 Oct 3, 4:27 PM
$CADL Better than Keytruda. This coming from the KOL mouth that predicted Keytruda would be game Changing. Now he says CAN-2409 is what they have been waiting for the last 20 years. $MRNA $XBI Listen to AUA. Listen from 17 minute mark and rest of call. Don’t miss out. $MRK https://edge.media-server.com/mmc/p/9fcro3ze/ Turning "Cold" Tumors "Hot": Cancers like prostate cancer are historically "cold," meaning they naturally suppress the immune system and don't respond well to immunotherapy drugs like Keytruda. A high abscopal effect would essentially act as an in-vivo vaccine, forcing the immune system to recognize the prostate cancer cells and attack them body-wide.
1 replies
Dulge_Gappana Oct 3, 3:34 PM
$MRNA the drug works--
1 replies
MonkeyBananaGenius Oct 3, 12:19 PM
$MRNA $RIVN $SG not too shabby for these picks. RIVN should catch up soon. Still only long RIVN and SG.
0 replies
Eye_Of_The_Tiger Oct 3, 12:57 AM
$MRNA Moderna to replace Warner Bros Discovery on Nasdaq 100 https://share.google/ZKPzk0psa8qSmkYgO
0 replies